GLSI · Greenwich LifeSciences, Inc.
$14.02
+1.22 (+9.53%)
At close · Jul 30
Going-concern doubt
— flagged Jun 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Jun 4, 2026
Market Cap
$205.79M
Shares
14.68M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $6,241,685 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $2,750,028 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $2,252,042 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $1,416,589 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Snehal Patel | CEO | $999,071 |
Key facts
CIK
1799788
CUSIP
396879108
13F (30d)
10 filings
10 filers
Visit website
Investor relations